Pyxis Oncology, Inc.
Index- P/E- EPS (ttm)-45.59 Insider Own8.00% Shs Outstand32.32M Perf Week14.22%
Market Cap78.73M Forward P/E- EPS next Y-3.74 Insider Trans-40.69% Shs Float24.99M Perf Month-10.11%
Income- PEG- EPS next Q-0.78 Inst Own58.40% Short Float1.37% Perf Quarter-56.39%
Sales- P/S- EPS this Y-501.70% Inst Trans3.42% Short Ratio1.97 Perf Half Y-79.89%
Book/sh7.23 P/B0.34 EPS next Y-4.70% ROA- Target Price18.00 Perf Year-
Cash/sh7.81 P/C0.32 EPS next 5Y- ROE- 52W Range1.96 - 19.00 Perf YTD-77.30%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-87.42% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low21.94% ATR0.28
Employees64 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)43.35 Volatility10.93% 11.27%
OptionableNo Debt/Eq0.00 EPS Q/Q-594.20% Profit Margin- Rel Volume0.18 Prev Close2.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume174.27K Price2.39
Recom1.80 SMA202.62% SMA50-28.37% SMA200-69.39% Volume27,463 Change-4.02%
Nov-02-21Initiated Jefferies Buy $25
Nov-02-21Initiated Credit Suisse Outperform $19
Nov-02-21Initiated BofA Securities Neutral $16
May-19-22 06:35AM  
May-13-22 08:03AM  
May-07-22 10:34AM  
Apr-27-22 06:35AM  
Apr-13-22 06:35AM  
Apr-08-22 01:05PM  
Mar-29-22 11:00AM  
Mar-22-22 06:35AM  
Jan-10-22 11:17AM  
Dec-15-21 08:00AM  
Dec-09-21 08:30AM  
Nov-15-21 07:15AM  
Nov-10-21 08:00AM  
Oct-08-21 03:31PM  
Oct-07-21 10:24PM  
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chin MarkFormer DirectorApr 21Sale3.051,745,7615,324,5710Apr 25 12:12 PM
Cline Darren SDirectorDec 08Buy9.3910,00093,88510,000Dec 09 04:18 PM
Civik ThomasDirectorNov 18Buy12.7415,700200,01815,700Nov 19 01:21 PM